"I'm not going to lay back and watch somebody die": a qualitative study of how people who use drugs' naloxone experiences are shaped by rural risk environment and overdose education/naloxone distribution intervention.


Journal

Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624

Informations de publication

Date de publication:
10 11 2023
Historique:
received: 30 08 2023
accepted: 04 11 2023
medline: 13 11 2023
pubmed: 10 11 2023
entrez: 10 11 2023
Statut: epublish

Résumé

Overdoses have surged in rural areas in the U.S. and globally for years, but harm reduction interventions have lagged. Overdose education and naloxone distribution (OEND) programs reduce overdose mortality, but little is known about people who use drugs' (PWUD) experience with these interventions in rural areas. Here, we analyze qualitative data with rural PWUD to learn about participants' experiences with an OEND intervention, and about how participants' perceptions of their rural risk environments influenced the interventions' effects. Twenty-nine one-on-one, semi-structured qualitative interviews were conducted with rural PWUD engaged in the CARE2HOPE OEND intervention in Appalachian Kentucky. Interviews were conducted via Zoom, audio-recorded, and transcribed verbatim. Thematic analysis was conducted, guided by the Rural Risk Environment Framework. Participants' naloxone experiences were shaped by all domains of their rural risk environments. The OEND intervention transformed participants' roles locally, so they became an essential component of the local rural healthcare environment. The intervention provided access to naloxone and information, thereby increasing PWUDs' confidence in naloxone administration. Through the intervention, over half of participants gained knowledge on naloxone (access points, administration technique) and on the criminal-legal environment as it pertained to naloxone. Most participants opted to accept and carry naloxone, citing factors related to the social environment (responsibility to their community) and physical/healthcare environments (overdose prevalence, suboptimal emergency response systems). Over half of participants described recent experiences administering intervention-provided naloxone. These experiences were shaped by features of the local rural social environment (anticipated negative reaction from recipients, prior naloxone conversations). By providing naloxone paired with non-stigmatizing health and policy information, the OEND intervention offered support that allowed participants to become a part of the healthcare environment. Findings highlight need for more OEND interventions; outreach to rural PWUD on local policy that impacts them; tailored strategies to help rural PWUD engage in productive dialogue with peers about naloxone and navigate interpersonal conflict associated with overdose reversal; and opportunities for rural PWUD to formally participate in emergency response systems as peer overdose responders. Trial registration The ClinicalTrials.gov ID for the CARE2HOPE intervention is NCT04134767. The registration date was October 19th, 2019.

Sections du résumé

BACKGROUND
Overdoses have surged in rural areas in the U.S. and globally for years, but harm reduction interventions have lagged. Overdose education and naloxone distribution (OEND) programs reduce overdose mortality, but little is known about people who use drugs' (PWUD) experience with these interventions in rural areas. Here, we analyze qualitative data with rural PWUD to learn about participants' experiences with an OEND intervention, and about how participants' perceptions of their rural risk environments influenced the interventions' effects.
METHODS
Twenty-nine one-on-one, semi-structured qualitative interviews were conducted with rural PWUD engaged in the CARE2HOPE OEND intervention in Appalachian Kentucky. Interviews were conducted via Zoom, audio-recorded, and transcribed verbatim. Thematic analysis was conducted, guided by the Rural Risk Environment Framework.
RESULTS
Participants' naloxone experiences were shaped by all domains of their rural risk environments. The OEND intervention transformed participants' roles locally, so they became an essential component of the local rural healthcare environment. The intervention provided access to naloxone and information, thereby increasing PWUDs' confidence in naloxone administration. Through the intervention, over half of participants gained knowledge on naloxone (access points, administration technique) and on the criminal-legal environment as it pertained to naloxone. Most participants opted to accept and carry naloxone, citing factors related to the social environment (responsibility to their community) and physical/healthcare environments (overdose prevalence, suboptimal emergency response systems). Over half of participants described recent experiences administering intervention-provided naloxone. These experiences were shaped by features of the local rural social environment (anticipated negative reaction from recipients, prior naloxone conversations).
CONCLUSIONS
By providing naloxone paired with non-stigmatizing health and policy information, the OEND intervention offered support that allowed participants to become a part of the healthcare environment. Findings highlight need for more OEND interventions; outreach to rural PWUD on local policy that impacts them; tailored strategies to help rural PWUD engage in productive dialogue with peers about naloxone and navigate interpersonal conflict associated with overdose reversal; and opportunities for rural PWUD to formally participate in emergency response systems as peer overdose responders. Trial registration The ClinicalTrials.gov ID for the CARE2HOPE intervention is NCT04134767. The registration date was October 19th, 2019.

Identifiants

pubmed: 37946233
doi: 10.1186/s12954-023-00900-z
pii: 10.1186/s12954-023-00900-z
pmc: PMC10636969
doi:

Substances chimiques

Naloxone 36B82AMQ7N
Narcotic Antagonists 0

Banques de données

ClinicalTrials.gov
['NCT04134767']

Types de publication

Clinical Trial Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

166

Subventions

Organisme : NIDA NIH HHS
ID : 4UH3DA044798-03
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

© 2023. The Author(s).

Références

Addiction. 2019 Dec;114(12):2267-2278
pubmed: 31307116
Int J Drug Policy. 2021 Apr;90:103080
pubmed: 33340947
Harm Reduct J. 2021 Jun 30;18(1):68
pubmed: 34193165
AIDS Behav. 2013 Sep;17(7):2341-51
pubmed: 23184464
Int J Drug Policy. 2014 Jan;25(1):157-65
pubmed: 23932166
Int J Drug Policy. 2009 May;20(3):193-201
pubmed: 19147339
Int J Drug Policy. 2020 Nov;85:102588
pubmed: 31753603
Am J Public Health. 2021 Aug;111(8):e1-e12
pubmed: 34214412
West J Emerg Med. 2021 Feb 08;22(2):339-345
pubmed: 33856321
Int J Drug Policy. 2018 Aug;58:46-54
pubmed: 29803097
Subst Abus. 2022;43(1):113-126
pubmed: 32243234
J Rural Health. 2023 Mar;39(2):328-337
pubmed: 36117151
Int J Drug Policy. 2019 Oct;72:47-54
pubmed: 31113713
Int J Drug Policy. 2019 Dec;74:144-151
pubmed: 31590090
Int J Drug Policy. 2015 Jan;26(1):92-9
pubmed: 25130869
Int J Drug Policy. 2017 Mar;41:19-28
pubmed: 28027483
Glob Implement Res Appl. 2021;1(3):209-222
pubmed: 34622215
Am J Public Health. 2006 Oct;96(10):1854-61
pubmed: 17008583
Int J Environ Res Public Health. 2021 Mar 05;18(5):
pubmed: 33807955
J Public Health Manag Pract. 2018 Jan/Feb;24(1):63-68
pubmed: 28257406
Harm Reduct J. 2020 Jan 9;17(1):4
pubmed: 31918740
Drug Alcohol Depend. 2021 Sep 1;226:108878
pubmed: 34214880
JAMA Netw Open. 2020 Feb 5;3(2):e1921227
pubmed: 32058549
JMIR Form Res. 2020 Dec 23;4(12):e22411
pubmed: 33355094
Pharmacy (Basel). 2021 Feb 02;9(1):
pubmed: 33540676
Drug Alcohol Depend. 2019 Nov 1;204:107581
pubmed: 31574407
Int J Drug Policy. 2020 Nov;85:102701
pubmed: 32223985
PLoS One. 2019 Nov 7;14(11):e0224686
pubmed: 31697736
Subst Abus. 2022;43(1):774-784
pubmed: 35112993
Addict Behav. 2018 Nov;86:79-85
pubmed: 29572041
Am J Public Health. 2023 Jan;113(S1):S43-S48
pubmed: 36696623
PLoS One. 2020 May 21;15(5):e0229208
pubmed: 32438390
J Opioid Manag. 2017 Jul/Aug;13(4):253-260
pubmed: 28953317
Harm Reduct J. 2007 Jan 25;4:3
pubmed: 17254345
Am J Drug Alcohol Abuse. 2020 May 3;46(3):273-288
pubmed: 31809217
Am J Public Health. 2016 Jul;106(7):1243-6
pubmed: 27077351

Auteurs

Zora Kesich (Z)

Rollins School of Public Health, Emory University, Atlanta, GA, 30322, USA. zkesich1@gmail.com.

Umedjon Ibragimov (U)

Rollins School of Public Health, Emory University, Atlanta, GA, 30322, USA.

Kelli Komro (K)

Rollins School of Public Health, Emory University, Atlanta, GA, 30322, USA.

Kenneth Lane (K)

College of Public Health, University of Kentucky, Lexington, KY, 40536, USA.

Melvin Livingston (M)

Rollins School of Public Health, Emory University, Atlanta, GA, 30322, USA.

April Young (A)

College of Public Health, University of Kentucky, Lexington, KY, 40536, USA.

Hannah L F Cooper (HLF)

Rollins School of Public Health, Emory University, Atlanta, GA, 30322, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH